Alcohol Use Disorder: Clinical Trials

52 trials for Alcohol Use Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

26 completed, 11 recruiting, 5 active not recruiting, 4 withdrawn. 52 Phase 1, 21 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 152Completed 26, Recruiting 11, Active not recruiting 5, Withdrawn 4, Terminated 3, Unknown 2, Not yet recruiting 1
Phase 221Completed 13, Recruiting 3, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1

Follow Alcohol Use Disorder: new trials by email Literature Review of Alcohol Use Disorder trials Research Report on Alcohol Use Disorder

Trials (filtered) newest first · largest first

All 52 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Environment and Alcohol: A Pilot Study
Evaluate the effects of Environmental Enrichment (EE) on alcohol consumption - Alcohol Use Disorder
Phase 1RecruitingNational Institute on Drug Abuse (NIDA)442026-11-192026-11-16
Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients
Sodium Acetate, Placebo - Alcohol Withdrawal, Alcohol Abstinence
Phase 1 / Phase 2Not yet recruitingUniversity of Colorado, Denver752026-11-012026-10-30
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
Semaglutide 1.0 mg - Alcohol Use Disorder, Weight Loss
Phase 1Active not recruitingYale University42026-03-262026-09-10
Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder
NTX-2001, Placebo - Alcohol Use Disorder
Phase 1RecruitingNewleos Therapeutics, Inc.502026-03-202026-04-09
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
Intravenous Ethanol, 18F-PF-06445974 - Alcohol Use Disorder
Phase 1RecruitingNational Institute of Mental Health (NIMH)302025-12-112026-11-02
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Oral disulfiram - Alcohol Use Disorder, Retinal Dystrophies
Phase 1RecruitingUniversity of Rochester152025-05-192026-09-16
A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects
CMND-100 - Alcohol Use Disorder
Phase 1 / Phase 2RecruitingClearmind Medicine Inc.842025-04-302026-03-31
PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder
18F-PF-06445974, Oxazepam - Alcohol Use Disorder
Phase 1RecruitingNational Institute of Mental Health (NIMH)302025-03-202026-10-27
Intranasal Insulin for Treatment of Alcohol Use Disorder
Regular Human Insulin then Placebo, Placebo then Regular Human Insulin - Alcohol Use Disorder
Phase 1 / Phase 2RecruitingBrown University402025-02-252026-09-30
PT150 Drug for Use in Alcohol Use Disorder
alcohol, Stress-Induction, PT150 - Alcohol Use Disorder
Phase 1RecruitingPop Test Oncology LLC342025-02-012026-09-16
Ketamine for Combined Depression and Alcohol Use Disorder
Ketamine Hydrochloride, Midazolam Hydrochloride - Depression, Alcohol Use Disorder
Phase 1 / Phase 2RecruitingUniversity Hospital of North Norway342025-01-202026-06-23
Enhancing the Effects of Alcohol Treatment With L-Carnitine
L-carnitine - Alcohol Use Disorder
Phase 1CompletedBrown University242024-09-272025-06-15
Treating Stress and Anxiety in Individuals With Alcohol Use Disorder (AUD)
active heat, Active c tactile fiber stimulation, sham heat - Anxiety Disorders, Alcohol Use Disorder
Phase 1UnknownSoovu Labs Inc.362024-07-152024-01-25
Apremilast for Alcohol Use Disorder Treatment in Women and Men
Apremilast - Alcohol Use Disorder
Phase 1Active not recruitingYale University102024-05-082026-02-03
A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine
Prazosin + cyproheptadine, KT110 - Alcohol Use Disorder
Phase 1CompletedKinnov Therapeutics122024-04-232025-03-13
rTMS in Older Adults With MCI and AUD
Active, Open Label iTBS-rTMS - Alcohol Use Disorder, Mild Cognitive Impairment
Phase 1Active not recruitingMedical University of South Carolina352023-11-012026-09-17
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
Brexanolone - PTSD, Alcohol Use Disorder
Phase 1Active not recruitingYale University252023-08-012025-10-14
Spironolactone in Alcohol Use Disorder (SAUD)
Placebo, Spironolactone - Alcohol Use Disorder
Phase 1RecruitingNational Institute on Drug Abuse (NIDA)202023-07-132026-11-09
Phase 1b Study of DCR-AUD in Healthy Volunteers
DCR-AUD, Placebo - Alcohol Use Disorder
Phase 1CompletedDicerna Pharmaceuticals, Inc., a Novo Nordisk company162023-01-292026-01-14
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
Intestinal Microbiota Transplant (IMT) Capsules, Placebo Capsules - Liver Disease; Alcohol-Related, Cirrhosis
Phase 1 / Phase 2Active not recruitingVirginia Commonwealth University802022-11-212026-08-24

Showing 20 of 52. Sign in to see all of them.

Narrower conditions

Alcoholism (52)  ·  Alcohol Drinking (6)  ·  Anxiety Disorders (4)  ·  Stress Disorders, Post-Traumatic (3)  ·  Alcohol-Related Disorders (2)  ·  Depressive Disorder, Major (2)  ·  Alcohol Abstinence (1)  ·  Behavior, Addictive (1)  ·  Cognition Disorders (1)  ·  Cognitive Dysfunction (1)  ·  Depression (1)  ·  Emergencies (1)  ·  Fibrosis (1)  ·  Inflammation (1)  ·  Liver Diseases (1)

Broader conditions

Chemically-Induced Disorders (52)  ·  Mental Disorders (52)  ·  Substance-Related Disorders (51)  ·  Alcohol-Related Disorders (50)  ·  Behavior (10)  ·  Drinking Behavior (7)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Pathologic Processes (4)  ·  Stress Disorders, Traumatic (3)  ·  Trauma and Stressor Related Disorders (3)  ·  Behavioral Symptoms (2)  ·  Depressive Disorder (2)  ·  Disease Attributes (2)  ·  Mood Disorders (2)  ·  Neurocognitive Disorders (2)

Interventions

Ethanol (6)  ·  Pioglitazone (3)  ·  Sugars (3)  ·  Cannabidiol (2)  ·  Ketamine (2)  ·  (11R,13S,17S)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta(a)phenanthren-3-one (1)  ·  Capsules (1)  ·  Carnitine (1)  ·  Cyproheptadine (1)  ·  Disulfiram (1)  ·  Doxazosin (1)  ·  Duloxetine Hydrochloride (1)  ·  Economics (1)  ·  Exenatide (1)  ·  Fecal Microbiota Transplantation (1)

Sponsors

Yale University (5)  ·  Brown University (4)  ·  Medical University of South Carolina (4)  ·  The University of Texas Health Science Center, Houston (4)  ·  Boston Medical Center (3)  ·  National Institute on Drug Abuse (NIDA) (3)  ·  NYU Langone Health (2)  ·  National Institute of Mental Health (NIMH) (2)  ·  University of California, Los Angeles (2)  ·  VA Office of Research and Development (2)  ·  Clearmind Medicine Inc. (1)  ·  Craig Rush (1)  ·  Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  Ihsan M Salloum, MD, MPH (1)

Countries

United States (45)  ·  France (1)  ·  Israel (1)  ·  Norway (1)  ·  United Kingdom (1)

Top investigators

Eric Devine, PhD (3)  ·  Lorenzo Leggio, M.D. (3)  ·  Jin H Yoon, PhD (2)  ·  Robert B Innis, M.D. (2)  ·  Andreas W Blomkvist, M.D. (1)  ·  Carolina L Haass-Koffler, PHARMD, PHD (1)  ·  Charles Marmar, MD (1)  ·  Craig Rush, PhD (1)  ·  E. Sherwood Brown, MD, PhD, MBA (1)  ·  Elizabeth Ralevski, PhD (1)  ·  Ellen Burnham, MD (1)  ·  Ethan Cowan, MD (1)  ·  Gihyun Yoon, MD (1)  ·  Ihsan Salloum, MD (1)

Results publications

PMID 31535696, PMID 39472130, PMID 39719161, PMID 40492610, PMID 40584152, PMID 40795937, PMID 42258258

NIH funding

U54AA027989 (2), 2016 (1), 2023 (1), K01AA026005 (1), K01AA026874 (1), P50AA010761 (1), P50DA009262 (1), R01AA024933 (1), R01AA026255 (1), R01AA026514 (1), R01AA027236 (1), R01AA029398 (1), R01AA030774 (1), R21AA024917 (1), R21AA026389 (1)